Welcome to our dedicated page for BXRX news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on BXRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BXRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BXRX's position in the market.
Baudax Bio (NASDAQ:BXRX) announced a virtual presentation of ANJESO™ (meloxicam) injection data at Digestive Disease Week (DDW) 2020. The findings show significant reductions in opioid use and hospital stay length by approximately one day when administered preoperatively for colorectal surgeries. Costs remained similar to placebo groups. ANJESO, approved by the FDA in February 2020, is expected to launch commercially by June 2020, addressing opioid-related issues with its non-addictive profile and analgesic effects.
Summary not available.